884306-77-8

Usage

Uses

Used in Pharmaceutical Industry:
(5-oxo-tetrahydro-pyran-3-yl)-carbamic acid benzyl ester is used as a reagent and intermediate for the synthesis of various pharmaceuticals. Its role in the creation of new drugs is crucial, particularly due to its potential as a cholinesterase inhibitor, which may aid in the development of treatments for neurological disorders.
Used in Agrochemical Industry:
In the agrochemical sector, (5-oxo-tetrahydro-pyran-3-yl)-carbamic acid benzyl ester is utilized as a reagent and intermediate in the production of agrochemicals. Its carbamate structure holds promise for the development of herbicides, contributing to more effective and targeted weed control solutions in agriculture.
Used in Organic Synthesis:
(5-oxo-tetrahydro-pyran-3-yl)-carbamic acid benzyl ester is employed as a key component in organic synthesis processes. Its unique structure allows it to participate in a variety of chemical reactions, making it a valuable asset in the synthesis of complex organic compounds for various applications.

Upstream product

• 621-84-1 O-benzyl carbamate 
• 98166-23-5 2H-pyran-3(6H)-one 
• 61363-56-2 2H-pyran-3,5(4H,6H)-dione 
• 1403864-09-4 benzyl N-(5-hydroxyoxan-3-yl)carbamate 
• 1403864-10-7 5-amino-tetrahydro-2H-pyran-3-ol 
• 265321-06-0 5-amino-2H-pyran-3(6H)-one 
• 688785-30-0 5-ethoxy-2H-pyran-3(6H)-one 
• 98-00-0 (2-furyl)methyl alcohol 
• 445378-38-1 3,6-dihydro-2H-pyran-3-ol 
• 329684-87-9 (±)-6-[(tert-butyldimethylsilyl)oxy]-3,6-dihydro-2H-pyran-3-one 
• 35436-57-8 6-hydroxy-3,6-dihydro-2H-pyran-3-one 

Downstream Products

• 884306-78-9 benzyl 3,4-dihydro-7-nitro-2H-pyrano[3,2-b]pyridin-3-ylcarbamate 
• 884306-79-0 benzyl 6,8-dihydro-3-nitro-5H-pyrano[3,4-b]pyridin-5-ylcarbamate 
• 1403864-09-4 benzyl N-(5-hydroxyoxan-3-yl)carbamate 
• 1403864-10-7 5-amino-tetrahydro-2H-pyran-3-ol 
• 1418199-75-3 5,5-difluoro-tetrahydro-pyran-3-ylamine 
• 1418199-74-2 (5,5-difluoro-tetrahydro-pyran-3-yl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

BCAT MODULATION

This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

Microwave-assisted synthesis of novel (5-nitropyridin-2-yl)alkyl and (5-nitropyridin-3-yl)alkyl carbamates

A straightforward approach to novel (5-nitropyridin-2-yl)alkyl and (5-nitropyridin-3-yl)alkyl carbamate building blocks is presented in this study. Their construction is achieved by condensation of N-carbamate a- and β-amino carbonyl derivatives with l-methyl-3,5-dinitro-2-pyridone 1 under microwave irradiation. Judiciously chosen modifications in the nature of the parent carbonyl starting material has influenced the regiochemical outcome of the reaction and allowed an efficient access to novel nitrogen-containing scaffolds. Compounds sharing morphological similarities have been gathered in three libraries differing from each other in a single structural parameter.

ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR

The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH2i O or S; E is CR6R7 or NR 3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4--alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4--alkenyl, formyl or C,-C3-alkylcarbonyl; R1a is H, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4 -cycloalkyl, or R1a and R2 together are (CH2)n with n being 2 or 3, or R1a and R2a together are (CH2)n with n being 2 or 3; R2 and R2a are independently of each other H, CH3, CH2F, CHF2 or CF3; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, C1-C2-alkyl and fluorinated C1-C2-alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.